Evidence map›Paper›PMID 34226834›Full record

ArticleRegulation & governance2021

Perspectives in the study of the political economy of COVID-19 vaccine regulation.

Elize M da Fonseca, Holly Jarman, Elizabeth J King, Scott L Greer

Abstract read
In one paragraph

Article in Regulation & governance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. How education and GDP drive the COVID-19 vaccination campaign.Archives of public health = Archives belges de sante publique · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elize M da FonsecaSao Paulo School of Business Administration Getulio Vargas Foundation Sao Paulo Brazil.ORCID https://orcid.org/0000-0003-3847-3105
Holly JarmanSchool of Public Health University of Michigan Ann Arbor MI USA.ORCID https://orcid.org/0000-0002-7330-3075
Elizabeth J KingSchool of Public Health University of Michigan Ann Arbor MI USA.ORCID https://orcid.org/0000-0001-8465-4607
Scott L GreerSchool of Public Health University of Michigan Ann Arbor MI USA.ORCID https://orcid.org/0000-0002-5288-0471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines against SARS-CoV-2 continue to be developed at an astonishingly quick speed and the early ones, like Pfizer and Moderna, have been shown to be more effective than many public health scientists had dared to hope. As COVID-19 vaccine research continues to progress, the world's eyes are turning toward medicine regulators. COVID-19 vaccines need to be authorized for use in each country in which the pharmaceutical industry intends to commercialize its product. This results in a patchwork of regulations that can influence the speed at which products are launched and the standards that govern them. In this research forum article, we discuss several key questions about COVID-19 vaccine regulations that should shape research on the next stage of the pandemic response. We call for a research agenda that looks into the political economy of pharmaceutical regulation, particularly from a comparative perspective, including Global South countries.

Indexed as

comparative politicsCOVID‐19pharmaceutical regulationpolitical economy

Identifiers

PMID34226834
PMCPMC8242737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.